文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

多西环素预防美国细菌性性传播感染:DoxyPEP多中心开放标签随机对照试验及开放标签延伸的最终结果

Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension.
PubMed 文献 · Lancet Infect Dis · 2025-03-24

在美国西雅图和旧金山开展的多中心开放标签随机对照试验,纳入637名过去一年至少感染过一次细菌性性传播感染的男男性行为者和跨性别女性,按2:1随机分配接受多西环素暴露后预防(doxy-PEP,无保护性行为后24–72小时服用200 mg多西环素缓释片)或标准诊疗。随机阶段多西环素组每季度细菌性性传播感染比例为12.0%,标准诊疗组为30.5%,相对危险度为0.39(95%CI 0.31–0.49,p<0.0001);开放标签延伸阶段两组分别为13%和17%。多西环素暴露后预防耐受性良好,未发现新的安全性信号。

要点

  • 随机阶段多西环素组细菌性性传播感染季度比例为12.0%,标准诊疗组为30.5%,相对危险度0.39(95%CI 0.31–0.49,p<0.0001)。
  • 开放标签延伸阶段,继续使用多西环素者季度感染比例为13%,标准诊疗组启动多西环素后为17%。
  • 淋球菌培养阳性者中,多西环素组四环素耐药8/29(27%),未使用组5/21(24%)。

核心结论

  • 多西环素暴露后预防可减少该男男性行为者和跨性别女性人群的细菌性性传播感染,在开放标签延伸阶段仍然有效。
  • 多西环素暴露后预防耐受性良好、接受度高,未发现新的安全性信号。

研究设计与样本

  • DoxyPEP为在美國西雅图和旧金山开展的多中心开放标签随机对照试验,按诊所2:1随机分配,并设有开放标签延伸阶段。
  • 纳入过去一年至少有一次细菌性性传播感染的男男性行为者和跨性别女性,随机阶段637人入组,592人完成至少一个随访季度(多西环素组411人、标准诊疗组181人),开放标签延伸阶段282人(多西环素组207人、标准诊疗组82人)。
  • 主要结局为每季度出现一种或以上细菌性性传播感染(淋病奈瑟菌、沙眼衣原体或早期梅毒),在意向治疗修正队列中评估。

主要发现

  • 随机阶段多西环素组1077个季度中129个(12.0%)检出性传播感染,标准诊疗组455个季度中139个(30.5%),绝对差异19个百分点,相对危险度0.39(95%CI 0.31–0.49,p<0.0001)。
  • 开放标签延伸阶段,继续使用多西环素者388个季度中51个(13%)诊断性传播感染,启动多西环素的标准诊疗组145个季度中25个(17%)。
  • 所有使用多西环素的季度中,出现1例2级实验室异常和5例3级不良事件,可能或很可能与多西环素暴露后预防相关;研究者未将任何严重不良事件归因于多西环素。
  • 研究中淋球菌培养阳性者中,使用多西环素者29例中8例(27%)对四环素耐药(最低抑菌浓度≥2 μg/mL),未使用者21例中5例(24%)耐药。

关键数值与推荐

  • 多西环素暴露后预防方案为无保护性行为后24–72小时服用200 mg多西环素缓释片。
  • 随机阶段主要结局相对危险度0.39(95%CI 0.31–0.49,p<0.0001),绝对差异19个百分点。
  • 四环素耐药定义为最低抑菌浓度≥2 μg/mL。

临床怎么用

  • 作者认为多西环素暴露后预防可减少该人群的细菌性性传播感染,且耐受性良好、接受度高、无新的安全性信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Doxycycline post-exposure prophylaxis (doxy-PEP) is a promising intervention to reduce bacterial sexually transmitted infections (STIs). We evaluated the effect of doxy-PEP on STI incidence and antimicrobial resistance in men who have sex with men and transgender women for up to 12 months of follow-up, inlcuding an open-label extension. METHODS: DoxyPEP, an open-label trial in Seattle (WA, USA) and San Francisco (CA, USA) among men who have sex with men and transgender women with at least one bacterial STI in the past year, randomly assigned participants by clinic (with computer-generated variable block sizes) 2:1 to doxy-PEP (200 mg doxycycline delayed-release tablets 24-72 h after condomless sex) or standard care. The independent endpoint adjudication committee was masked to group assignment. The primary outcome was presence of one or more bacterial STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, or early syphilis) each quarter. This outcome was assessed in the modified intention-to-treat cohort, which included participants with at least one follow-up quarter (ie, ∼3 months) in their as-randomised assignment. After early termination of the randomised phase for efficacy, all participants still enrolled were offered doxy-PEP in an open-label extension (OLE). We report quarterly incidence of bacterial STIs for the as-randomised and OLE periods. Safety was assessed in all participants with any follow-up data. The trial was registered with ClinicalTrials.gov (NCT03980223) and is completed. FINDINGS: From Aug 19, 2020, to May 13, 2022, we enrolled 637 participants; 592 participants completed at least one follow-up quarter in the randomised phase (411 in the doxy-PEP group and 181 in the standard-care group) and 282 in the OLE phase (207 in the doxy-PEP group and 82 in the standard-care group). STIs were present in 129 (12·0%) of 1077 quarters in the doxy-PEP group versus 139 (30·5%) of 455 quarters in the standard-care group during the as-randomised period, showing an absolute difference of 19 percentage points and a relative risk of 0·39 (95% CI 0·31-0·49, p<0·0001). During the OLE, STIs were diagnosed in 51 (13%) of 388 quarters among those continuing doxy-PEP and 25 (17%) of 145 quarters among standard-care participants who initiated doxy-PEP. Throughout all quarters for participants on doxy-PEP, there was one grade 2 laboratory abnormality and five grade 3 adverse events that were possibly or probably related to doxy-PEP. No serious adverse events were attributed by site investigators to doxycycline. Of participants with positive gonorrhoea cultures during the study, eight (27%) of 29 taking doxy-PEP versus five (24%) of 21 not taking doxy-PEP had tetracycline resistance (minimum inhibitory concentration ≥2 μg/mL). INTERPRETATION: Doxy-PEP was effective in reducing bacterial STIs in this population of men who have sex with men and transgender women, including during an open-label extension when doxy-PEP efficacy was known. Doxy-PEP was well tolerated, highly acceptable, and with no new safety signals. FUNDING: US National Institutes of Health.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Luetkemeyer AF, Donnell D, Cohen SE, et al. Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension. Lancet Infect Dis. 2025. PMID: 40147465. doi:10.1016/S1473-3099(25)00085-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。